Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO

Joaquín Martínez
Joaquín Martínez Jefe de Unidad de Investigación Clínica
T +34 917328000 (Ext )
jmartinezl@ext.cnio.es

Investigadores

  • Santiago Barrio
  • Lucia Virginia Fernández
  • Miguel Gallardo
  • María Linares

Investigador Clínico I

  • Rosa María Ayala
  • María Calbacho
  • Gonzalo Carreño
  • María Pilar Carreras
  • María Teresa Cedena
  • Francisco Javier De La Serna
  • Carlos Grande
  • Ana Jiménez
  • María Inmaculada Rapado
  • Antonia Rodríguez
  • Ricardo Sánchez

Becarios Post-doctorales

  • Almudena García
  • Alejandra Leivas
  • Yanira Ruiz
  • Antonio Valeri
  • María Velasco

Becarios Pre-Doctorales

  • Pedro Aguilar
  • Noemí Álvarez
  • Eva Castellano
  • Laura Córdoba
  • Jessica Encinas
  • Roberto García
  • Marta Ibáñez
  • Elena Maroto
  • Michael Ochieng
  • María Alejandra Ortiz
  • Alba Rodríguez
  • Laura Sánchez

Técnicos de Laboratorio

  • Raquel Ancos
  • Natalia Sofía Buenache
  • Sara Dorado
  • Adrián Fernández
  • Vanesa Garrido
  • Alicia Giménez
  • María Luz Morales
  • Laura Moreno
  • Miguel Ángel Navarro
  • Juan Manuel Rosa
  • Laura Rufián

Recently, the field of haematology has been gaining traction in cancer research, not only for the study of critical disease affecting human health, but also for its implications in solid cancers and the applicability of haematological tools to other areas.

In terms of cancer implications, immune cells play a remarkable role in metastasis, inflammation, and immune surveillance. In fact, this concept triggered the development of the most promising cancer therapy of the 21st century, immunotherapy.

Moreover, the haematology research area has been developing cutting-edge applications such as liquid biopsy, an easy peripheral blood/plasma analysis that can anticipate the appearance of disease, or the emergence of tumour clones in relapsed patients.

The following main lines of research define our laboratory:

  • Liquid biopsy, minimal residual disease, and next-generation sequencing.
  • Immunotherapy: NK/T-CAR, BITES and immune checkpoints in haematological and paediatric cancers.
  • Role of hnRNP K, master regulator of tumourigenesis.
  • Viral infection and cancer.

Publicaciones

Subir